Skip to Main Content
Back to News

Lobbying Update: $320,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed

None

$320,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025"

You can find more data on corporate lobbying on Quiver Quantitative.

BBIO Insider Trading Activity

BBIO insiders have traded $BBIO stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

  • GENETIC DISORDER L.P. KKR sold 5,800,000 shares for an estimated $149,350,000
  • NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 4 sales selling 54,778 shares for an estimated $1,290,081.
  • BRIAN C STEPHENSON (Secretary, Treasurer & CFO) has made 0 purchases and 3 sales selling 8,311 shares for an estimated $195,726.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

BBIO Hedge Fund Activity

We have seen 139 institutional investors add shares of BBIO stock to their portfolio, and 105 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles